Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label FLCN. Show all posts
Showing posts with label FLCN. Show all posts

Saturday, January 5, 2013

Research update: FLCN-FNIP2-AMPK and MNU-induced apoptosis

This isn't going to help you but by understanding this we might be  able to prevent apoptosis in the neuronal cascade of death. So it might be useful to find out this prior to our next stroke. Ask your researcher.
http://www.bhdsyndrome.org/forum/bhd-research-blog/research-update-flcn-fnip2-ampk-and-mnu-induced-apoptosis/
Previous studies in mouse cell lines have suggested that FLCN, FNIP2 and AMPK are involved in N-methyl-N-nitrosourea (MNU)-induced apoptosis (Lim et al., 2011 – described here). Using a human cell line, further work from the same group has now shown that FNIP2 appears to be stabilised by MNU treatment, and that this stability is modulated by FLCN and AMPK (Sano et al., 2012).
Sano et al. used a HeLa MR cell line which lacks the enzyme MGMT that repairs MNU-induced DNA lesions, and confirmed that FNIP2 is involved in the induction of apoptosis following MNU exposure (using flow cytometry with miRNA-knockdown). Western blot analysis went on to show that FNIP2 protein levels gradually increased after MNU treatment, while those of FLCN and AMPKα remained unchanged. However, qRT-PCR showed no change in the levels of FNIP2 mRNA after MNU treatment, indicating that the observed increase in FNIP2 protein levels was not due to transcriptional effects. Using HeLa MR cells which expressed FLAG-tagged FNIP2, it could be seen that the proteosome inhibitor MG132 led to a significant increase in FNIP2 protein levels, while inhibiting protein synthesis with cyclohexamide led to a significant decrease. In both cases, the levels of FLCN and AMPKα remained constant. Consequently, the authors suggested that FNIP2 may be regulated at the post-transcriptional level following MNU exposure.
As FNIP2 is known to interact with FLCN and AMPK (Hasumi et al., 2008; Takagi et al., 2008; Lim et al., 2011), the authors investigated whether these factors affected the levels of FNIP2. siRNA knockdown of FLCN in HeLa MR cells led to a decrease in FNIP2 protein levels, and treatment with MNU elicited no significant changes. In contrast, siRNA knockdown of AMPKα led to an increase in FNIP2 levels, which increased further after MNU treatment. Together these results suggest that FLCN and AMPK may have opposing effects on the stability of FNIP2. Moreover, the inhibition of AMPK kinase activity with compound C led to an increase in the levels of FNIP2, but no increase was observed after MNU exposure. This result suggests that the kinase activity of AMPK is also linked to the stability of FNIP2.
Finally, immunoprecipitation of FLAG-tagged FNIP2 from HeLa MR cells treated with MNU over 72 hours showed that FLCN interacted with FNIP2 throughout this period. However, it could be seen that the interaction between FNIP2 and AMPKα gradually decreased over the same timescale. Although the exact mechanistic details appear to be quite complex, it is clear that FLCN, FNIP2 and AMPK are associated with MNU-induced apoptosis in vitro.